Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence modelPediatric MS patients with a primary progressive-like disease may still have relevant inflammatory activity and may benefit from regular MS treatmentDistinct Effector Programs of Brain-Homing CD8+ T Cells in Multiple SclerosisOcrelizumab associates with reduced cerebrospinal fluid B and CD20dim CD4+ T cells in primary progressive multiple sclerosisDisease activity in primary progressive multiple sclerosisReal-world challenges in the diagnosis of primary progressive multiple sclerosis
author
type
label
Beatrijs Ha Wokke
firstName
Beatrijs Ha